دورية أكاديمية
The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: a randomised comparative trial.
| العنوان: | The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: a randomised comparative trial. |
|---|---|
| المؤلفون: | Nor Azlin MI; Department of Obstetrics and Gynaecology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. azlinm@mail.hukm.ukm.my, Maryasalwati I, Norzilawati MN, Mahdy ZA, Jamil MA, Zainul Rashid MR |
| المصدر: | Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology [J Obstet Gynaecol] 2008 May; Vol. 28 (4), pp. 424-6. |
| نوع المنشور: | Comparative Study; Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8309140 Publication Model: Print Cited Medium: Internet ISSN: 1364-6893 (Electronic) Linking ISSN: 01443615 NLM ISO Abbreviation: J Obstet Gynaecol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: [Bristol, England] : Wright, PSG, |
| مواضيع طبية MeSH: | Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use , Cyclooxygenase Inhibitors/*therapeutic use , Dysmenorrhea/*drug therapy , Mefenamic Acid/*therapeutic use , Pyridines/*therapeutic use , Sulfones/*therapeutic use, Adult ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Cross-Over Studies ; Cyclooxygenase Inhibitors/adverse effects ; Etoricoxib ; Female ; Humans ; Mefenamic Acid/adverse effects ; Pyridines/adverse effects ; Sulfones/adverse effects |
| مستخلص: | Dysmenorrhoea is painful menstruation that occurs in 45-72% of all women. This was a prospective randomised study of the efficacy of etoricoxib (Arcoxia) compared with mefenamic acid (Ponstan) in treating primary dysmenorrhoea. All single, sexually inactive women with primary dysmenorrhoea were randomised into two groups (mefenamic acid and etoricoxib) of pain relief and underwent a cross-over study. The success of treatment as evidenced by pain relief, the side-effects and complications were observed and analysed. Some 80% (20 women) had significantly better pain relief with etoricoxib, compared with only 20 per cent in the mefenamic acid group (p = 0.007). Etoricoxib has significantly fewer side-effects compared with mefenamic acid (p = 0.005) with significantly reduced menstrual blood loss (p = 0.025). In conclusion, etoricoxib is a better treatment for primary dysmenorrhoea with better pain relief, less menstrual blood loss and fewer side-effects compared with mefenamic acid. |
| المشرفين على المادة: | 0 (Anti-Inflammatory Agents, Non-Steroidal) 0 (Cyclooxygenase Inhibitors) 0 (Pyridines) 0 (Sulfones) 367589PJ2C (Mefenamic Acid) WRX4NFY03R (Etoricoxib) |
| تواريخ الأحداث: | Date Created: 20080708 Date Completed: 20080908 Latest Revision: 20220419 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1080/01443610802150051 |
| PMID: | 18604680 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1364-6893 |
|---|---|
| DOI: | 10.1080/01443610802150051 |